Analysts/Institutional Investor Meet/Con. Call Updates

Registered Office: 103, Akruti Arcade, Opposite A H Wadia High School, Near Azad Nagar Metro Station, Andheri (West), Mumbai –400058. Tel: 022 61437991 | Email: info@laxmidentallimited.com; co.sec@laxmidentallimited.com | Website: www.laxmidentallimited.com CIN No: L51507MH2004PLC147394 | GST No: 27AABCL0001A1ZL Date: November 07, 2026 Listing Department Listing & Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mumbai – 400001 Plot No. C/1, “G” Block BSE Scrip Code: 544339 Bandra-Kurla Complex Bandra (E), Mumbai – 400 051 Symbol: LAXMIDENTL Re: LAXMI DENTAL LIMITED - ISIN: INE0WO601020 Dear Sir(s)/Madam(s), Sub: - Transcript of the Q2FY27 and H1FY27 Earnings Conference Call of Laxmi Dental Limited (“Company”). Further to our intimations dated October 28, 2026 and November 04, 2026 and pursuant to the provisions of Regulation 30 read with Para A Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI Listing Regulations”), we are enclosing the Transcript of the ‘Q2FY27 and H1FY27 Earnings Conference Call’ (i.e., Post Earnings/Quarterly Call), held on Wednesday, November 04, 2026 at 10:00 A.M. (IST), wherein, inter-alia, the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026, were discussed. The aforementioned transcript of the ‘Q2FY27 and H1FY27 Earnings Conference Call’ (i.e., Post Earnings/Quarterly Call) is also uploaded on the Company’s website at https://laxmidentallimited.com/for-investors. Kindly take the above on record. Thanking you, For Laxmi Dental Limited -------------------------------------------------- Suman Saha Company Secretary and Compliance Officer ICSI Membership Number: A33035 Encl.: As above. “Laxmi Dental Limited Q2 FY27 Earnings Conference Call” November 04, 2026 “E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recordings uploaded on the stock exchange on November 04, 2026, will prevail.” MANAGEMENT: MR. RAJESH KHAKHAR – CHAIRPERSON AND WHOLE- TIME DIRECTOR – LAXMI DENTAL LIMITED MR. SAMEER MERCHANT – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – LAXMI DENTAL LIMITED MR. DHARMESH DATTANI – CHIEF FINANCIAL OFFICER – LAXMI DENTAL LIMITED Page 1 of 19 Laxmi Dental Limited November 04, 2026 Moderator: Ladies and gentlemen, good day and welcome to Laxmi Dental Limited Q2 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. I now hand the conference over to Mr. Rajesh Khakhar, Chairperson and Whole-Time Director. Thank you, and over to you, sir. Rajesh Khakhar: Thank you. Good morning, everybody. A warm welcome to all of you, and thanks for joining our earnings call. I would like to take this opportunity to wish everyone a very happy and a prosperous Diwali. On this call, we are joined by our MD and CEO, Sameer Merchant, CFO Mr. Dharmesh Dattani and Strategic Growth Advisor, our Investor Relations Advisors. The results and the presentations are uploaded on the stock exchange and company website. I hope everybody has had a chance to look at them. I am delighted to share that Q2 FY27 was another positive quarter for us. Building on the healthy start we made for FY27, we have delivered steady growth, healthy profitability, and continued progress on the strategic priorities we have laid out for the year. Our revenue for Q2 FY27 stood at INR79.5 crores, recording a highest-ever quarterly revenue as well as EBITDA. Our EBITDA for the quarter grew by 38.5% and PAT grew by 17.6%. EBITDA and PAT margin for the quarter stood at 19.2% and 12.6% respectively. This improvement in profitability is a result of a better product mix and our continued focus on operational efficiency. The growth was broad-based across our core dental segments: dental laboratory, aligner solutions, and pediatric dental products. This is exactly how we had envisaged our digital strategy to play out. The scanners deployed with our dental partners over the past few years were meant to deepen our connection with this clinic and create higher recurring opportunities across our laboratory and aligner business. We are now seeing that ecosystem translate into consistent recurring business. I am also happy to say that both our dental lab and aligner business deliver solid performance during the quarter. Our domestic dental lab, international lab, as well as Bizdent, our clear aligner business, delivered its highest-ever quarterly revenue. Sameer will take you through the segment details shortly. Page 2 of 19 Laxmi Dental Limited November 04, 2026 Moving on to an important update on our IPO proceeds, we successfully got shareholders' approval for updating the objects and extending the timeline for utilization. I would like to thank all our shareholders for the strong support and the confidence they have placed in us. The unutilized IPO fund of INR48.1 crores will now be deployed towards building our own manufacturing infrastructure, above INR27 crores towards acquisition of land and constructions of building and infrastructure for dental laboratory and aligner manufacturing facilities, and above INR21 crores towards machinery, computer equipment, and other movable assets for the existing and new facilities. This deployment is planned across FY27 and FY28. Dentistry today is at a defining moment with digital technologies, artificial intelligence, and precision manufacturing transformation clinical practices. As India's only fully integrated dental product company, we remain focused on our growth strategies across geographies product innovations, market reach, quality standards, and achievement in our operations to create better efficiency and scalability. Now I will request Sameer to give you some more color on our business performance during the quarter. Thank you. Sameer Merchant: Thank you, Rajesh bhai. Happy Diwali to everyone. Speaking about our segmental performance for the quarter. Our dental lab business grew by 22.7% Y-o-Y, with a solid growth of 32% in the international lab and 15% in our domestic lab business. In the domestic market, the growth is driven by increasing digital adoption and deeper engagement with our dental partners through our hub-and-spoke model. Our digital penetration in the domestic lab business has reached around 78%, and remains firmly on track towards our medium-term target of over 90%. Every scanner deployed does far more than digitize impression. It strengthens our connection with the dentist, improves accuracy, and enhances workflow efficiency. In international markets, the momentum reflects the strong relationship and market presence we have built across USA, the UK, and Europe over the years. Along with our growing partnership with dental service organizations, we are also preparing for our participation in the International Dental Show in Cologne, Germany towards the end of the fiscal year, which will provide an excellent platform to showcase our products and further expand our global network. The cost of this event is already budgeted in our full-year marketing expense. Our aligner solution business recorded a healthy growth of 23.5% YOY during the quarter. Within this segment, Bizdent, our brande [Showing first 8,000 characters — download PDF for full document]